Abstract
Brain metastases represent one of the most common intracranial malignancies, yet early and accurate detection remains challenging, particularly in clinical datasets with limited availability of healthy controls. In this study, we developed a feature-based machine learning framework to classify patients with and without brain metastases using multi-modal clinical MRI scans. A dataset of 50 subjects from the UCSF Brain Metastases collection was analyzed, including pre- and post-contrast T1-weighted images and corresponding segmentation masks. We designed advanced feature extraction strategies capturing intensity, enhancement patterns, texture gradients, and histogram-based metrics, resulting in 44 quantitative descriptors per subject. To address the severe class imbalance (46 metastasis vs. 4 non-metastasis cases), we applied minority oversampling and noise-based augmentation, combined with stratified cross-validation. Among multiple classifiers, Random Forest consistently achieved the highest performance with an average accuracy of 96.7% and an area under the ROC curve (AUC) of 0.99 across five folds. The proposed approach highlights the potential of handcrafted radiomic-like features coupled with machine learning to improve metastasis detection in heterogeneous clinical MRI cohorts. These findings underscore the importance of methodological strategies for handling imbalanced data and support the integration of feature-based models as complementary tools for brain metastasis screening and research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of the University of California, San Francisco (UCSF) gave ethical approval for the creation and sharing of the UCSF Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI dataset, which was used in this study. The dataset is fully de-identified and publicly available to researchers upon request through the UCSF Imaging Data Commons portal. Therefore, no additional ethical approval was required for the present analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
mh.shafiabadi{at}iau.ac.ir
Data Availability
The MRI data analyzed in this study are part of the University of California, San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset, which is publicly available to qualified researchers upon request through the UCSF Imaging Data Commons portal: https://imagingdatasets.ucsf.edu/dataset/1 . The dataset is fully de-identified. Additional data generated in this work (e.g., processed feature sets and code) are available from the corresponding author upon reasonable request.
